

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	1	of	9	Attorney Docket Number	15270J-004743US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1215	2009/0297511	12-03-2009	Schenk	
	1192	7,582,733	09-01-2009	Basi et al.	
	1216	2009/0155256	6-18-2009	Black et al.	
	1169	2009/0142270 A1	06-04-2009	Schroeter et al.	
	1210	2007/0072307 A1	03-29-2007	Godavarti et al.	
	1096	2007/0021454 A1	01-25-2007	Coburn et al.	
	1196	7,147,851 B1	12-12-2006	Ponath et al.	
	1153	2006/0234912	10-16-2006	Wang et al.	
	1197	7,112,661 B1	09-26-2006	Miller	
	1154	2006/0182321	08-17-2006	Hu et al.	
	1155	2006/0121038	06-08-2006	Schenk et al.	
	1099	2006/0057701 A1	03-16-2006	Rosenthal et al.	
	1098	2005/0090648 A1	04-28-2005	Tsurushita et al.	
	1195	6,824,780 B1	11-30-2004	Devaux et al.	
	1101	2003/0054484 A1	03-20-2003	Fong et al.	
	1170	2003/0009104 A1	01-09-2003	Hyman et al.	
	1211	6,432,710 B1	08-13-2002	Boss, Jr. et al.	
	1116	6,057,098	05-02-2000	Buechler et al.	
	1131	6,015,662	01-18-2000	Hackett et al.	
	1209	5,910,427	06-08-1999	Mikayama	
	1148	5,773,007	06-30-1998	Penney et al.	
	1147	5,723,130	03-03-1998	Hancock et al.	
	1168	5,620,844	04-15-1997	Neurath et al.	
	1160	5,472,693	12-05-1995	Gourlie et al.	

U.S. PATENT APPLICATIONS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1212	60/530,480	12-17-2003	Arumugham	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

62486858-11 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.B./

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	2	of	9	Attorney Docket Number	15270J-004743US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	1102	EP	1 690 547	A1	08-16-1998			<input type="checkbox"/>
	1176	EP	616 814	A1	03-21-1994			<input type="checkbox"/>
	1175	EP	613007	A2	02-18-1994	Duplicate. Do not print.		<input type="checkbox"/>
	1135	WO	08/131298	A3	12-18-2008			<input type="checkbox"/>
	1107	WO	08/131298	A2	10-30-2008			<input type="checkbox"/>
	1133	WO	06/042158	A	04-20-2006			<input type="checkbox"/>
	1146	WO	05/035753	A	04-21-2005			<input type="checkbox"/>
	1206	WO	04/016282	A1	2-26-2004			<input type="checkbox"/>
	1152	WO	01/78777	A2	10-25-2001			<input type="checkbox"/>
	1177	WO	97/40147	A1	10-30-1997			<input type="checkbox"/>
	1178	WO	97/37031	A1	10/09/1997			<input type="checkbox"/>
	1179	WO	97/36601	A1	10/09/1997			<input type="checkbox"/>
	1180	WO	97/28816	A1	08-14-1997			<input type="checkbox"/>
	1173	WO	97/18855	A1	05-29-1997			<input type="checkbox"/>
	1151	WO	96/39834	A1	12-19-1996			<input type="checkbox"/>
	1181	WO	96/29421	A1	09-26-1996			<input type="checkbox"/>
	1182	WO	96/14061	A1	05-17-1996			<input type="checkbox"/>
	1183	WO	94/21288	A1	09-29-1994			<input type="checkbox"/>
	1184	WO	94/16731	A1	08-04-1994			<input type="checkbox"/>
	1185	WO	94/09823	A1	05-11-1994			<input type="checkbox"/>
	1186	WO	92/15330	A1	09-17-1992			<input type="checkbox"/>
	1187	WO	92/07944	A1	05-14-1992			<input type="checkbox"/>
	1188	WO	92/05793	A1	04-16-1992			<input type="checkbox"/>
	1189	WO	90/14837	A1	12-13-1990			<input type="checkbox"/>
	1174	WO	90/14840	A1	12-13-1990			<input type="checkbox"/>
	1190	WO	87/06838	A1	11-19-1987			<input type="checkbox"/>
	1145	WO	87/02671	A	05-07-1987			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

62486858-1 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K.B./

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	3	of	9	Attorney Docket Number	15270J-004743US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1156	ALLEN et al., "Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer," Arch. Neurol., 63(10): 1475-1478 (2006), abstract only.	<input type="checkbox"/>
	1120	ARMOUR et al., "Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activates," J. Immunol., 29:2613-2624 (1999).	<input type="checkbox"/>
	1117	AVIS, "Parenteral Preparations," Remington's Pharmaceutical Sciences, 17:1518-1519 (1985).	<input type="checkbox"/>
	1191	BIEWENGA et al., "Cleavage of Protein A-binding IgA1 with IgA1 Protease From Streptococcus Sanguls," Immunol Commun., 12(5):491-500 (1983), abstract only.	<input type="checkbox"/>
	1207	BORRAS-CUESTA et al., "Engineering of Immunogenic Peptides by Co-Linear Synthesis of Determinants Recognized by B and T Cells," Eur. J. Immunol., 17:1213-1215 (1987)	<input type="checkbox"/>
	1138	BRINKMAN, "Splice Variants as Cancer Biomarkers," Clinical Biochemistry, 37(7):584-594 (2004).	<input type="checkbox"/>
	1204	BUTTINI et al., "β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease," The Journal of Neuroscience, 25(40):9096-9101 (2005).	<input type="checkbox"/>
	1110	CHEN et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen," J. Mol. Biol., 293:865-881 (1999).	<input type="checkbox"/>
	1142	CHOI et al., "A Generic Intron Increases Gene Expression in Transgenic Mice," Molecular and Cellular Biology, 11(6):3070-3074 (1991).	<input type="checkbox"/>
	1132	Corcoran et al., "Overexpression of hAPPswe Impairs Rewarded Alternation and Contextual Fear Conditioning in a Transgenic Mouse Model of Alzheimer's Disease," Learn Mem. 9(5):243-252:2000.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	4	of	9	Attorney Docket Number	15270J-004743US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1144	DATABASE Geneseq, "Nucleotide Sequence of a Variable Heavy Chain of IgG4," EBI Accession No. GSN:ADZ51216 (2005).	<input type="checkbox"/>
	1100	Dialog/Derwent, Abstract of WPI Acc No: 1995-261292/199534: Novel monoclonal antibody against human high-affinity IgE receptor – and DNA fragment encoding the MAb, for the specific identification of human Fc-epsilon RI, Derwent WPI database (1995).	<input type="checkbox"/>
	1194	Ecuadorian Search Report of 07/02/2009 for Ecuador Patent Application No. SP 03-4685.	<input type="checkbox"/>
	1137	Extended European Search Report of 12/18/08 for European Application 05812436.6-1212.	<input type="checkbox"/>
	1136	European Examination Report of 09/23/2008 for European Application 04776252.1-2405.	<input type="checkbox"/>
	1130	European Examination Report as part of 12-08-2008 communication for European Application 04720353.4	<input type="checkbox"/>
	1134	European Examination Report of 11/20/2008 for European Application 08011409.3	<input type="checkbox"/>
	1150	Family and legal status of EP0613007, Inpadoc Search (2009).	<input type="checkbox"/>
	1097	FRAGIONE et al., "Familial cerebral amyloid angiopathy related to stroke and dementia. <u>Amyloid</u> , 8(Suppl 1):36-42 (2001), abstract only.	<input type="checkbox"/>
	1163	Genbank Accession number AAA69734, Schroeder et al., "Immunoglobulin heavy chain [Homo sapiens], Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 07/11/95.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	5	of	9	Attorney Docket Number	15270J-004743US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	1164	Genbank Accession number BAC01733, Akahori et al., "Immunoglobulin kappa light chain VLJ region [Homo sapiens]", 07/02/02.	<input type="checkbox"/>	
	1208	GHETIE et al., "CD4 Peptide-Protein Conjugates, But Not Recombinant Human CD4, Bind to Recombinant gp120 From the Human Immunodeficiency Virus in the Presence of Serum From AIDS Patients," <i>Proc. Natl. Acad. Sci.</i> , 88:5690-5693 (1991).	<input type="checkbox"/>	
	1205	GOLDING et al., "Vaccine Strategies: Targeting Helper T Cell Responses," <i>Annals New York Academy of Sciences</i> , 31:126-137 (1995).	<input type="checkbox"/>	
	1118	HEZAREH et al., "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <i>Journal of Virology</i> , 24(75):12161-12168 (2001).	<input type="checkbox"/>	
	1200	HILLEN-MASKE et al., "Konichalcit", <i>Rompp Chemie Lexikon</i> , 9 th edition, pg. 2322 (1990).	<input type="checkbox"/>	
	1193	HOGARTH, Fc Receptors Are Major Mediators of Antibody Based Inflammation in Autoimmunity," <i>Current Opinion in Immunology</i> , 14:798-802 (2002).	<input type="checkbox"/>	
	1127	JANEWAY et al., <i>Immunobiology</i> , 3 rd edition, pages 8:18-8:19 (1997).	<input type="checkbox"/>	
	1121	MANN et al., "Atypical Amyloid (ABeta) Deposition in the cerebellum in Alzheimer's Disease: An Immunohistochemical Study Using End-Specific ABeta Monoclonal Antibodies," <i>ACTA Neuropathologica</i> , 91:647-653 (1996).	<input type="checkbox"/>	
	1122	MANN et al., "Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene," <i>The American Journal of Pathology APR</i> , 4(148): 1257-1266 (1996).	<input type="checkbox"/>	
	1157	MAVRAGANI et al., "A Case of Reversible Posterior Leucoencephalopathy Syndrome After Rityximab Infusion," <i>Rheumatology</i> , 43(11) 1450-1451 (2006).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	6	of	9	Attorney Docket Number	15270J-004743US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	1198	MITCHELL et al., "Prevention of Intracerebral Hemorrhage," <u>Current Drug Targets</u> , 8(7):832-838 (2007).	<input type="checkbox"/>	
	1201	MUTSCHLER et al., "Arzneimittel-Wirkungen, Lehrbuch der Pharmakologie und Toxikologie," Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 6 th edition, pgs. 651-656 (1991), (German Article).	<input type="checkbox"/>	
	1139	MYERS et. al., "Targeting Immune Effector Molecules to Human Tumor Cells Through Genetic Delivery of 5T4-Specific SCFV Fusion Proteins," <u>Cancer Gene Therapy</u> , 9(11):884-896 (2002).	<input type="checkbox"/>	
	1167	PADLAN et al., "Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL-10 Fab-lysozyme Complex, <u>Immunology</u> , 86:5938-5942 (1989).	<input type="checkbox"/>	
	1171	PANGALOS et al., "Disease Modifying Strategies for the Treatment of Alzheimer's Disease Targeted at Modulating Levels of β -amyloid Peptide," <u>Biochemical Society Transactions</u> , 33(4):553-558 (2005).	<input type="checkbox"/>	
	1108	PASCALIS et al., "Grafting of "Abbreviated" Complementarity-Determining Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," <u>The Journal Immunology</u> , 169:3076-3084 (2002).	<input type="checkbox"/>	
	1158	PCT Written Opinion of 12/22/2008 for application PCT/US2008/80370.	<input type="checkbox"/>	
	1214	PCT International Preliminary Report on Patentability (Chapter I) of 10/20/2009 with Written Opinion of 10/03/2008 for application PCT/US2008/060926.	<input type="checkbox"/>	
	1159	PCT Search Report of 01/22/2009 for application PCT/US2008/80370.	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	7	of	9	Attorney Docket Number	15270J-004743US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	1213	PCT Search Report of 10/09/2008 for application PCT/US2008/060926.		<input type="checkbox"/>
	1172	PRADA et al., "Antibody-Mediated Clearance of Amyloid- β Peptide From Cerebral Amyloid Angiopathy Revealed by quantitative in Vivo Imaging," Journal of Neuroscience, 27(8):1973-1980 (2007).		<input type="checkbox"/>
	1149	QU et al., "A β_{42} gene Vaccine Prevents A β_{42} deposition in brain of Double Transgenic Mice," J. Neurological Sciences, 260:204-213 (2007).		<input type="checkbox"/>
	1199	RIECHMANN et al., "Reshaping Human Antibodies for Therapy," Nature, 332:323-327 (1988).		<input type="checkbox"/>
	1141	ROBBINS et al., "The Intronic Region of an Incompletely Spliced gp100 Gene Transcript Encodes an Epitope Recognized by Melanoma-Reactive Tumor-Infiltrating Lymphocytes," Journal of Immunology, 159(1):303-308 (1997).		<input type="checkbox"/>
	1202	SAIDO et al., "Autolytic Transition of μ -Calpain Upon Activation as Resolved by Antibodies Distinguishing Between the Pre- and Post-Autolysis Forms," J. Biochem., 111:81-86 (1992).		<input type="checkbox"/>
	1123	SCHMIDT et al., "Monoclonal Antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains," The American Journal of Pathology, 1(151):69-80 (1997).		<input type="checkbox"/>
	1165	SCHROEDER et al., "Preferential Utilization of Conserved Immunoglobulin Heavy Chain Variable Gene Segments During Human Fetal Life," Immunology, 87:6146-6150 (1990).		<input type="checkbox"/>
	1140	SEABROOK et al., "Species-specific Immune response to Immunization with Human Versus rodent Abeta Peptide," Neurobiology of Aging, 25(9) 1141-1151 (2004)		<input type="checkbox"/>
	1119	Shepherd et al., "The design of the humanized antibody," Monoclonal Antibodies: A Practical Approach 58-66 (2000)		<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	8	of	9	Attorney Docket Number	15270J-004743US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	1104	SIDHU, "Page display in pharmaceutical biotechnology," <u>Current Opinion in Biotechnology</u> , 11:610-616 (2000).	<input type="checkbox"/>	
	1105	SMITH et al., "Phage Display," <u>Chemical Reviews, American Chemical Society</u> , 97(2):391-410 (1997).	<input type="checkbox"/>	
	1203	SOOD et al., "Synthetic Peptides: A Modern Approach to Vaccination," <u>Indian Journal of Experimental Biology</u> , 34:849-861 (1998).	<input type="checkbox"/>	
	1128	STUDNICKA et al., "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementary-modulating residues," <u>Protein Eng.</u> , 7(6):805-814 (1994), Abstract only.	<input type="checkbox"/>	
	1124	TAMAOKA et al., "Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH)," <u>Neurobiology of Aging</u> , 3(17):405-414 (1996).	<input type="checkbox"/>	
	1162	TRANG et al., "Pharmacokinetics of a Mouse/Human Chimeric Monoclonal Antibody (C-17-1A) in Metastatic Adenocarcinoma Patients," <u>Pharmaceutical Research</u> 7(6):587-592 (1990).	<input type="checkbox"/>	Duplicate reference
	1112	U.S. Application No. 09/316,387, Office Action mailed 09/10/2007.	<input type="checkbox"/>	
	1113	U.S. Application No. 09/316,387, Response to 06-20-2005 Office Action filed 12-20-2005.	<input type="checkbox"/>	
	1114	U.S. Application No. 09/316,387, Declaration of Solomon, Hrncic, and Wall under 37 C.F.R. § 1.131 filed 03-06-2006.	<input type="checkbox"/>	
	1115	U.S. Application No. 09/316,387, Office Action mailed 06/20/2005.	<input type="checkbox"/>	
	1109	Vajdos et al., "Comprehensive Functional Maps of the Antigen-binding site of an Anti_ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis," <u>J. Mol. Biol.</u> , 320:415-428 (2002).	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,319
				Filing Date	November 27, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Ballard, Kimberly
Sheet	9	of	9	Attorney Docket Number	15270J-004743US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	1143	WARD et al., "Spontaneous Deletions In IG Heavy Chain Genes Flanking Sequences Influence Splice Site Selection Nucleic Acids Research," 19(23): 6475-6480 (1991).	<input type="checkbox"/>	
	1161	Wikipedia entry for Antibody, retrieved April 27, 2009 from http:// http://en.wikipedia.org/wiki/Antibody .	<input type="checkbox"/>	
	1106	WILSON et al., "Phage display: applications, innovations, and issues in phage and host biology," <u>Can. J. Microbiol.</u> , 44:313-329 (1998).	<input type="checkbox"/>	
	1111	WU et al., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," <u>J. Mol. Biol.</u> , 294:151-162 (1999).	<input type="checkbox"/>	
	1125	YANAGISAWA K et al., "Amyloid BETA-protein (Alpha-Beta) associated with lipid molecules: immunoreactivity distinct from that of soluble Alpha-Beta," FEBS Letters, 1(420): 43-46 (1997).	<input type="checkbox"/>	
	1126	YANG et al., "Monoclonal Antibody to the C-terminus of Beta-Amyloid," Neuroreport, 16(5):2117-2120 (1994).	<input type="checkbox"/>	

Examiner Signature	/Kimberly Ballard/	Date Considered	12/15/2010
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.